Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Jun 13, 2022 7:34am
197 Views
Post# 34751042

RE:RE:RE:RE:Deliberate Obfuscation

RE:RE:RE:RE:Deliberate Obfuscation

BTW thanks to the ever-vigilant Eoganacht for highlighting the following Presentation to be given by Sherri on the 27th of this month - i.e. the day before the AGM. Hopefully this may answer some of the expressed uncertainties in advance of our Meeting:

 

9:10 am - 9:35 am

Sherri McFarland (The University of Texas at Arlington, United States)

"Clinical Update on TLD1433, a Metallodrug Photosensitizer for Treating Non-Muscle Invasive Bladder Cancer with Photodynamic Therapy"

 

Also worth listening to another Eoganach highlight and Sherri`s explanation of why the refractory NMIBC setting was chosen for the current Trial:

 

https://anchor.fm/utascience/episodes/Voices-Live--Talking-Chemistry-with-UTAs-Frank-Foss-and-Sherri-McFarland-e1hdfip

<< Previous
Bullboard Posts
Next >>